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 Origin of the Types and Groups of HIV and Its 
Epidemiology 
 HIV-1 
 HIV is subdivided into two types, HIV-1 and HIV-2. 
HIV-1 was transmitted to man by at least 4 zoonotic 
transmissions, groups M–P, of the corresponding chim-
panzee virus. This transmission occurred around 1930 
( 8 20 years), estimated from the molecular biological 
phylogenetic data available  [1] . The chimpanzee virus 
SIVcpz might date back to many thousands of years ago. 
It is a recombinant virus built up in its gag and pol part 
from the simian immunodeficiency virus (SIV) of red-
capped mangabey monkeys  (Cercocebus torquatus) and 
in its env part from SIVgsn or SIVmon of the greater spot-
nose monkey  (Cercopithecus nicticans) or mona monkey 
 (Cercopithecus mona) , respectively. SIV-infected chim-
panzees in regions of central Africa have evolved to dif-
ferent subspecies  (Pan troglodytes troglodytes and  P. trog-
lodytes schweinfurthii) . After the separation of groups of 
chimpanzees by big rivers, their SIVcpz viruses diverged 
and only the SIVs of  P. troglodytes troglodytes  chimpan-
zees seem to be ancestors of the various HIVs. The pres-
ence of an HIV-like retrovirus in around 5% of these an-
imals indicates a coevolution of host and virus over a long 
period of time  [2] . In most chimpanzees SIVcpz is ap-
athogenic  [3] . SIVcpz was hitherto not found in the chim-
panzee subspecies  P. troglodytes vellerosus and  P. troglo-
dytes verus .
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 Abstract 
 HIV-1 is a chimpanzee virus which was transmitted to hu-
mans by several zoonotic events resulting in infection with 
HIV-1 groups M–P, and in parallel transmission events from 
sooty mangabey monkey viruses leading to infections with 
HIV-2 groups A–H. Both viruses have circulated in the human 
population for about 80 years. In the infected patient, HIV 
mutates, and by elimination of some of the viruses by the ac-
tion of the immune system individual quasispecies are 
formed. Along with the selection of the fittest viruses, muta-
tion and recombination after superinfection with HIV from 
different groups or subtypes have resulted in the diversity of 
their patterns of geographic distribution. Despite the high 
variability observed, some essential parts of the HIV genome 
are highly conserved. Viral diversity is further facilitated in 
some parts of the HIV genome by drug selection pressure 
and may also be enhanced by different genetic factors, in-
cluding HLA in patients from different regions of the world. 
Viral and human genetic factors influence pathogenesis. Vi-
ral genetic factors are proteins such as Tat, Vif and Rev. Hu-
man genetic factors associated with a better clinical out-
come are proteins such as APOBEC, langerin, tetherin and 
chemokine receptor 5 (CCR5) and HLA B27, B57, DRB1 * 1303, 
KIR and PARD3B.  Copyright © 2012 S. Karger AG, Basel 
 Published online: January 24, 2012 
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 As a result of its spread and evolution in man, HIV-1 
group M has been subdivided into subtypes A–K, where 
subtypes E and I are missing since they are circulating 
recombinant forms (CRF)  [1, 4] . According to genetic re-
latedness there are 2 great lineages in HIV groups, M and 
N, and O and P. People carrying group N and P viruses 
are very rare, with, currently in Cameroon, about 20 and 
3 infected people, respectively. Group O virus infections 
are prevalent in about 0.1–1% of the sexually active popu-
lation in Cameroon; some infected individuals have also 
been identified in the neighboring countries of Gabon 
and Equatorial Guinea.
 HIV-1 group M has a worldwide distribution with cur-
rently more than 35 million infected people. A higher 
prevalence of all subtypes is found in sub-Saharan Africa, 
of subtype B in North and South America and Western 
Europe, of subtype A in Eastern Europe, of subtype C in 
southern Africa and India and of subtype A/E (CRF01) in 
southeast Asia  [5] . Group M subtype C is worldwide the 
most prevalent HIV-1, but rare subtypes may occur in all 
countries.
 Diagnostic tools, i.e. tests for antibody detection, viral 
load measurement and resistance determination, are 
mainly based on subtype B; this aspect needs to be con-
sidered along with the fact that other subtypes are preva-
lent in certain countries of the world, when tests are in-
terpreted as well in the choice of drugs for patient treat-
ment, i.e. non-nucleoside reverse-transcriptase inhibitors 
for subtype C.
 HIV-2 
 The origin of HIV-2 is SIVsmm, the SIV of sooty 
mangabey monkeys  (Cercocebus atys) in West Africa  [6] . 
Today HIV-2 is divided into the groups A–H, of which A 
and B are the most prevalent and perhaps the only patho-
genic ones. The easiest explanation for the presence of 
these groups in humans is that the independent and sep-
arate zoonotic transmission of a virus of each group to 
humans and further spread amongst humans by sexual 
transmission. Calculations of the nucleic acid sequence 
data estimated the date of introduction of HIV-2 in hu-
mans to 1940 ( 8 20 years), which is very close to the pre-
dicted introduction of HIV-1  [7] . HIV-2 is less pathogen-
ic than HIV-1, which results in a prolonged period until 
the signs of immunodeficiency and AIDS develop, and a 
mother-to-child transmission rate of around 7‰ to 2%, 
compared to 10–40% in those infected with HIV-1  [8] . 
The prevalence of HIV-2 in some African communities 
has reached approximately 10–16% over time, but this is 
currently being overtaken by HIV-1  [9] . HIV-2 is rare out-
side of West Africa, Mozambique, Angola and southwest 
India. A few people might be coinfected with both virus-
es, and HIV-2 does not induce immunity to prevent HIV-
1 superinfection, nor vice versa  [10] ; doubly infected pa-
tients develop an immunodeficiency and all the signs of 
AIDS earlier. Until now, a recombinant virus composed 
of parts of HIV-1 and HIV-2 has not been found in hu-
mans.
 Mutation Rate and Quasispecies 
 The replication cycle of HIV within the cytoplasm of 
a susceptible CD4 T lymphocyte, macrophage or dendrit-
ic cell starts after entry into the cell and cleavage of the 
core followed by synthesis of one new DNA strain. The 
reverse transcriptase (RT) synthesizes the first DNA 
strain using the viral RNA as a template. After RNA di-
gestion by the RNase activity the RT synthesizes the sec-
ond complementary strand. Finally, the double-stranded 
DNA molecule (proviral DNA) is released into the nucle-
us and integrated into the human host cell genome  [11] .
 The RT part of the polymerase has some enzymatic 
peculiarities: first, an error-prone activity during RNA-
DNA transcription that is combined with a preference to 
incorporate G in favor of A  [12] , and second, to jump and 
attach onto some neighboring nucleic acids so that dele-
tions, and to some extent insertions, occur frequently  [12, 
13] . The error rate is about 1 in 10,000 nucleotides  [13, 14] , 
which means that in each replication cycle in which the 
reverse transcription is involved, statistically one false 
nucleotide is incorporated in the HIV genome. Some 
parts of the 3-dimensional configurations of the enzymes 
and of structural proteins of HIV are essential for func-
tion. These regions are highly conserved, whereas other 
parts are tolerant to mutations. Examples of highly con-
served structures are parts of long-terminal repeats, ac-
tive enzymatic parts of the RT and integrase and p24 pro-
tein parts needed for condensation of the core; examples 
of hypervariability are parts of the envelope proteins 
gp120 and gp41, particularly the V3 loop in gp120 [15] .
 Selection Pressure by Antiretroviral Drugs 
 The antiretroviral treatment with nucleoside RT in-
hibitors induces a selection pressure in parts of the RT 
that are close to the enzymatic pocket in a direction such 
that the wild-type enzyme is inhibited by the drugs, and 
thus HIVs carrying wild-type RT are no longer produced. 
HIV strains with a mutated enzyme that are resistant to 
the drug will continue to replicate and adapt, and most 
replicate as fast as the wild-type virus. In a similar way, a 
mutated HIV strain can escape from the action of the im-
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mune system which is favored when random mutations 
are found in the gp120 protein, especially in the crown of 
the V3 loop. Usually for the first 5 years after infection, 
those HIV strains that are not cleared by immune action 
continue to replicate and will contribute to the HIV qua-
sispecies population found in the sexual and cerebral 
compartment and in the blood [16, 17] .
 Finally, there are certain parts of the HIV genome, 
noncoding (long-terminal repeat) or coding regions for 
proteins, e.g. accessory proteins, where mutations are tol-
erated. As a consequence of rapid HIV replication, a 
cloud of mutated viruses accumulates after the first 6 
months in the organism of the HIV-infected person. The 
formed quasispecies are all still, for example, HIV-1 M 
subtype B. Some of these members of the HIV quasispe-
cies are eliminated by antiretroviral treatment with a de-
cay half-life time in resting activated CD4 cells and 
CD14+ monocytes of around 20 months  [18] ; meanwhile, 
new HIVs are generated by new mutations and will over-
grow and replace the circulating population  [16] . This cy-
cle of generation of new quasispecies is ongoing until the 
AIDS stage is reached, when finally one population be-
comes dominant and causes severe CD4 cell depletion. 
The formation of quasispecies is not restricted to HIV but 
may be seen in other chronic infections with RNA virus-
es as well, e.g. influenza, hepatitis C and the picornavirus 
 [19, 20] .
 Recombination 
 A frequent action of a retrovirus to enlarge its genetic 
repertoire is the formation of recombinants. When a cell 
gets infected by two genetically different HIV-1 viruses, 
the RT may use both RNA templates for the first strand 
synthesis. As a consequence, a recombinant virus is 
formed harboring parts of the genome of strain 1 and 
strain 2. A recombination event in one cell occurs in 1 in 
400 HIV particles produced  [21, 22] . There might be some 
regions of preselection where it occurs  [22] . Recombina-
tion between the different members of a quasispecies, in-
cluding drug-resistant strains, is a frequent event. A new-
ly formed recombinant HIV might be very stable  [23] as 
is the case for the chimpanzee virus which is the origin 
of HIV-1, for the CRF01 which is a recombinant of A and 
E, for CRF02 which is a recombinant of A and G, and for 
CRF17 which did not change during the 20 years of fol-
low-up in Cameroon [4, 24] .
 New recombinants occurring after 1990 between dif-
ferent group M subtypes have been found frequently 
around the world as CRF07 and 08 (BC) in China, 
CRFF12, 28 and 29 (BF) in Argentina and Brazil, or mix-
tures of 3 different subtypes  [24] . Recombinants between 
group M and group O have been found in Cameroon. As 
mentioned above, natural recombinants between HIV-1 
and HIV-2 have not been found, despite the fact that these 
can be formed artificially in the laboratory  [24] . Recom-
bination is a frequent event in other RNA viruses, e.g. 
flavivirus, influenza virus (reassortment) and reovirus 
 [26] .
 Superinfection 
 Cellular Level 
 After entry into a cell, HIV alters the cell metabolism. 
One of the actions triggered by the Nef protein is the in-
ternalization of CD4 molecules expressed on the surface 
of the cell, accompanied by inhibiting or retarding the 
transport of newly synthesized CD4 molecules to the cell 
membrane  [27] . By this mechanism, superinfection of an 
already infected cell with a further HIV is impaired but 
still continues  [28] .
 Patient Level 
 Superinfection of an HIV-infected person with a new-
ly acquired HIV, e.g. by sexual transmission, has been 
observed frequently [29] . The immunity established by 
the first infecting HIV strain remains incomplete due to 
viral mutation, which is in turn due to a lack of efficient-
ly neutralizing antibodies and primed CD8 lymphocytes 
incapable of killing all HIV infected cells, especially those 
in the sanctuary sites  [30, 31] . Thus, a multi-drug-resis-
tant strain is also able to superinfect an HIV-infected pa-
tient, and as a result, a multi-drug-resistant HIV profile 
may be seen during follow-up in a patient who previous-
ly had a virus with a susceptible drug profile  [23, 32, 33] .
 Genetic Repertoire Influencing the Replication of HIV 
 Viral Factors 
 Several accessory proteins support and accelerate HIV 
replication which is usually called viral fitness  [34] . The 
most effective of these proteins is Tat, which acts as viral 
transcriptional transactivator, Rev, which regulates the 
RNA transport and Vif, which promotes viral maturation 
and release from the cell. None of these 3 proteins is in-
volved in the formation of drug resistance.
 Human Factors 
 Due to mutations (single nucleotide polymorphism) in 
the human genome the genetic background is heteroge-
neous. Proteins involved in the suppression of HIV rep-
lication and pathogenesis are: APOBEC3 – an apolipo-
protein B mRNA-editing, enzyme-catalytic, polypep-
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tide-like 3 enzyme which interferes with Vif  [35] , 
langerin – CD 207, a type II transmembrane protein of 
Langerhans cells in the mucosa and epidermis that binds 
by a lectin-mannose action to HIV glycoproteins and ac-
celerates internalization and subsequent degradation of 
the particle  [36] , tetherin – CD317, a human cellular pro-
tein capable of inhibiting HIV replication by interfering 
with Vpu, catching the freshly released HIV particle at 
the cell surface and forcing endocytosis and degradation 
 [37] and CCR5 – chemokine receptor 5, which, when 
lacking at the cell surface, delays lymphocyte attachment 
of HIV R5 strains that use it as a coreceptor together with 
the CD4 molecule  [36] . The capability of an R5 virus to 
adhere to the amino acid motif of the V3 loop of gp120 
can easily be determined by nucleic acid sequencing and 
thus the inhibitory capacity of  maraviroc, for example, 
can be determined  [39] . Human genetic factors of 
the immune system that influence progression of the 
HIV disease are HLA molecules, HLA B27, B5901 and 
DRB1 * 1303  [40] . Further genetic factors associated with 
single nucleotide polymorphism that might be protective 
or enhancing have been found in PARD3B, RANTES and 
KIR  [41] .
 Both viral and human genetic factors contribute to 
HIV pathogenesis and some of the viral factors are rou-
tinely identified by nucleic acid sequencing as targets to 
estimate and improve the outcome of the HIV-infected 
patient. To analyze human genetic factors besides CCR5, 
APOBEC and HLA might be a future challenge for those 
involved in the determination of HIV drug resistance.
 
 References 
 1 Korber B, Muldoon M, Theiler J, Gao F, Gup-
ta R, Lapedes A, Hahn BH, Wolinsky S, Bhat-
tacharya T: Timing the ancestor of the HIV-1 
pandemic strains. Science 2000; 288: 1789–
1796. 
 2 Neel C, Etienne L, Li Y, Takehisa J, Rudicell 
RS, Bass IN, Moudindo J, Mebenga A, Este-
ban A, van Heuerswyn F, Liegeois F, Kran-
zusch PJ, Walsh PD, Sanz CM, Morgan DB, 
Ndjango JBN, Plantier JC, Locatelli S, Gonder 
MK, Leendertz FH, Boesch C, Todd A, Dela-
porte E, Mpoudi-Ngole E, Hahn BH, Peeters 
M: Molecular epidemiology of simian immu-
nodeficiency virus infection in wild-living 
gorillas. J Virol 2010; 84: 1464–1476. 
 3 Etienne L, Nerrienet E, LeBreton M, Bibila 
GT, Foupouapouognigni Y, Rousset D, Nana 
A, Djoko CF, Tamoufe U, Aghokeng AF, 
Mpoudi-Ngole E, Delaporte E, Peeters M, 
Wolfe ND, Ayouba A: Characterization of a 
new simian immunodeficiency virus strain 
in a naturally infected  Pan troglodytes trog-
lodytes chimpanzee with AIDS related 
symptoms. Retrovirology 2011; 8: 4. 
 4 Brennan CA, Bodelle P, Coffey R, Devare SG, 
Golden A, Hackett J, Harris B, Holzmayer V, 
Luk KC, Schochetman G, Swanson P, Yama-
guchi J, Vallari A, Ndembi N, Ngansop C, 
Makamche F, Mbanya D, Gürtler LG, Zek-
eng L, Kaptue L: The prevalence of diverse 
HIV-1 strains was stable in Cameroonian 
blood donors from 1996 to 2004. J Acquir 
Immune Defic Syndr 2008; 49: 432–439. 
 5 UNAIDS/WHO. http://www.who.int/hiv/
pub/epidemiology/pubfacts. 
 6 Fultz PN, McClure HM, Anderson DC, 
Swenson RB, Anand R, Srinivasan A: Isola-
tion of a T-lymphotropic retrovirus from 
naturally infected sooty mangabey monkeys 
 (Cercocebus atys) . Proc Natl Acad Sci USA 
1986; 83: 5286–5290. 
 7 Lemey P, Pybus OG, Wang B, Saksena NK, 
Salemi M, Vandamme AM: Tracing the ori-
gin and history of the HIV-2 epidemic. Proc 
Natl Acad Sci USA 2003; 100: 6588–6592. 
 8 Burgard M, Jasseron C, Matheron S, Da-
mond F, Hamrene K, Blanche S, Faye A, 
Rouzioux C, Warszawski J, Madelbrot L: 
Mother-to-child transmission of HIV-2 in-
fection from 1986 to 2007 in the ARNS 
French Perinatal Cohort EPF-CO1. Clin In-
fect Dis 2010; 51: 833–843. 
 9 Tienen C, van der Loeff MS, Zaman SM, 
Vincent T, Sarge-Njie R, Peterson I, Leliqdo-
wicz A, Jave A, Rowland-Jones S, Aaby P, 
Whittle H: Two distinct epidemics: the rise 
of HIV-1 and decline of HIV-2 infection be-
tween 1990 and 2007 in rural Guinea-Bissau. 
J Acquir Immune Defic Syndr 2010; 53: 640–
647. 
 10 Gunthard HF, Huber M, Kuster H, Shah C, 
Schüppach J, Trkola A, Böni J: HIV-1 super-
infection in an HIV-2-infected woman with 
subsequent control of HIV-1 plasma viremia. 
Clin Infect Dis 2009; 48:e117–e120. 
 11 Iordanskiy S, Wattke M, Feng Y, Wood C: 
Subtype-associated differences in the HIV-1 
reverse transcription affect the viral replica-
tion. Retrovirology 2010; 7: 85. 
 12 Pathak VK, Temin HW: Broad spectrum of 
in vivo forward mutations, hypermutations, 
and mutational hotspots in a retroviral shut-
tle vector after a single replication cycle: sub-
stitutions, frameshifts, and hypermuta-
tions. Proc Natl Acad Sci USA 1990; 87: 
 6019–6023. 
 13 Pathak VK, Temin HM: Broad spectrum of 
in vivo forward mutations, hypermutations, 
and mutational hotspots in a retroviral shut-
tle vector after a single replication cycle: de-
letions and deletions with insertions. Proc 
Natl Acad Sci USA 1990; 87: 6024–6028. 
 14 Alvarez M, Matamoros T, Menendez-Arias 
L: Increased thermostability and fidelity of 
DNA synthesis of wild-type and mutant 
HIV-1 group O reverse transcriptases. J Mol 
Biol 2009; 392: 872–884. 
 15 Shimizu N, Okamoto T. Moriyama EN, 
Takeuchi Y, Gojobori T, Hoshino H: Patterns 
of nucleotide substitutions and implications 
for the immunological diversity of human 
immunodeficiency virus. FEBS Lett 1989; 
 250: 591–595. 
 16 Kijak GH, Simon V, Balfe P, Vanderhoeven J, 
Pampuro SE, Zala C, Ochoa C, Cahn P, Mar-
kowitz M, Salomom H: Origin of human im-
munodeficiency virus type 1 quasispecies 
emerging after antiretroviral treatment in-
terruption in patients with therapeutic fail-
ure. J Virol 2002; 76: 7000–7009. 
 17 Buzon MJ, Wrin T, Codoner FM, Dalmau J, 
Phung P, Bonjoch A, Coakley E, Clotet B, 
Martinez-Picado J: Combined antiretroviral 
therapy and immune pressure lead to in vivo 
HIV-1 recombination with ancestral viral 
genomes. J Acquir Immune Defic Syndr 
2011; 57: 109–117. 
 18 Zhu T, Muthui D, Holte S, Nickle D, Feng F, 
Brodie S, Hwangbo Y, Mullins JI, Corey L: 
Evidence for human immunodeficiency vi-
rus type 1 replication in vivo in CD14+ 
monocytes and its potential role as a source 
of virus in patients on highly active antiret-
roviral therapy. J Virol 2002; 76: 707–716. 
 19 Duarte EA, Novella IS, Weaver SC, Domingo 
E, Wain-Hobson S, Clarke DK, Moya A, Ele-
na SF, de la Torre JC, Holland JJ: RNA virus 
quasispecies: significance for viral disease 
and epidemiology. Infect Agents Dis 1994; 3: 
 201–214. 
 HIV: Origin of Types and Groups and 
Epidemiology 
Intervirology 2012;55:79–83 83
 20 Law M, Murayama T, Lewis J, Giang E, Tarr 
AW, Stamataki Z, Gastaminza P, Chisari FV, 
Jones IM, Fox RI, Ball JK, McKeating JA, 
Kneteman NM, Burton DR: Broadly neutral-
izing antibodies protect against hepatitis C 
virus quasispecies challenge. Nat Med 2008; 
 14: 25–27. 
 21 Onafuwa-Nuga A, Telesnitzky A: The re-
markable frequency of human immunodefi-
ciency virus type 1 genetic recombination. 
Microbiol Mol Biol Rev 2009; 73: 451–480. 
 22 Simon-Loriere E, Martin DP, Weeks KM, 
Negroni M: RNA structures facilitate recom-
bination-mediated gene swapping in HIV-1. 
J Virol 2010;84: 12675–12682. 
 23 Fang G, Weiser B, Kuiken C, Philpott SM, 
Rowland-Jones S, Plummer F, Kimani J, Shi 
B, Kaul R, Bwayo J, Anzala O, Burger H: Re-
combination following superinfection by 
HIV-1. AIDS 2004; 18: 153–159. 
 24 Kuiken C, Leitner T, Foley B, Hahn B, Marx 
P, McCutchan F, Wolinsky S, Korber B 
(eds): HIV Sequence Compendium. Los Ala-
mos National Laboratory, Los Alamos, 
2009http://www.hiv.lanl.gov/. 
 25 Motomura K, Chen J, Hu WS: Genetic re-
combination between human immunodefi-
ciency virus type 1 (HIV-1) and HIV-2, two 
distinct human lentiviruses. J Virol 2008; 82: 
 1923–1933. 
 26 Domingo E: Mechanism of viral emergence. 
Vet Res 2010; 41: 38–52. 
 27 Dai L, Stevenson M: A novel motif in HIV-1 
Nef that regulates MIP-1beta chemokine re-
lease in macrophages. J Virol 2010; 84: 8327–
8331. 
 28 Bocharov G, Ford NJ, Edwards J, Breinig T, 
Wain-Hobson S, Meyerhans A: A genetic-
algorithm approach to simulating human 
immunodeficiency virus evolution reveals 
the strong impact of multiple infected cells 
and recombination. J Gen Virol 2005; 86: 
 3109–3118. 
 29 Van der Kuyl AC, Kozacynska K, van den 
Burg R, Zorgdrager F, Back N, Juriaans S, 
Berkhout B, Reiss P, Cornelissen M: Triple 
HIV-1 infection. N Engl J Med 2005; 352: 
 2557–2559. 
 30 Batmanian J, Brew BJ: Clinical significance 
of central nervous system as sanctuary site 
for HIV. J HIV Ther 2005; 10: 16–21. 
 31 Dahl V, Josefsson L, Palmer S: HIV reser-
voirs, latency and reactivation: prospects for 
eradication. Antiviral Res 2010; 85: 286–294. 
 32 Smith DM, Wong JK, Hightower GK, Ignacio 
C, Koelsch KK, Petropoulos CJ, Richman 
DD, Little SJ: HIV drug resistance acquired 
through superinfection. AIDS 2005;  19: 
 1251–1256. 
 33 Rachinger A, Stolte IG, van de Ven TD, Burg-
er JA, Prins M, Suitemaker H, van’ t Wout 
AB: Absence of HIV-1 superinfection 1 year 
after infection between 1985 and 1997 coin-
cides with a reduction in sexual risk behav-
iour in the seroincident Amsterdam Cohort 
of homosexual men. Clin Infect Dis 2010; 50: 
 1309–1315. 
 34 Lorenzo-Redondo R, Borderia AV, Lopez-
Galindez C: Dynamics of in vitro fitness re-
covery of HIV-1. J Virol 2011; 85: 1384–1390. 
 35 Henriet S, Mercenne G, Bernacchi S, Paillart 
JC, Marquet R: Tumultous relationship be-
tween the human immunodeficiency virus 
type 1 viral infectivity factor (Vif) and the 
human APOBEC-3G and APOBEC-3F re-
striction factors. Microbiol Mol Biol Rev 
2009; 73: 211–232. 
 36 Van der Vlist M, Geijtenbeek TB: Langerin 
functions as an antiviral receptor on Langer-
hans cells. Immunol Cell Biol 2010; 88: 410–
415. 
 37 Sauter D, Specht A, Kirchhoff F: Tetherin. 
Holding on and letting go. Cell 2010; 141: 
 392–398. 
 38 Sterjovski J, Churchill MJ, Roche M, Ellett A, 
Farrugia W, Wesselingh SL, Cunnigham AL, 
Ramsland PA, Gorry PR: CD4-binding site 
alterations in CCR5-using HIV-1 envelopes 
influencing gp120-CD4 interactions and fu-
sogenicity. Virology 2011; 410: 418–428. 
 39 Swenson LC, Mo T, Dong WW, Zhong X, 
Woods CK, Jensen MA, Thielen A, Chapman 
D, Lewis M, James I, Heera J, Valdez H, Har-
rigan PR: Deep sequencing to infer HIV-1 
co-receptor usage: application to three clini-
cal trials of maraviroc in treatment-experi-
enced patients. J Infect Dis 2011; 203: 237–
245. 
 40 Julg B, Moodley ES, Oi Y, Ramduth D, Reddy 
S, Mncube Z, Gao X, Goulder PJ, Detels R, 
Ndungu T, Walker BD, Carrington M: Pos-
session of HLA class II DRB1 * 1303 associates 
with reduced viral loads in chronic HIV-1 
clade C and B infection. J Infect Dis 2011; 203: 
 803–809. 
 41 Troyer JL, Nelson GW, Lautenberger JA, 
Chinn L, McIntosh C, Johnson RC, Sezgin E, 
Kessing B, Malasky M, Hendrickson SL, Li 
G, Pontius J, Tang M, An P, Winkler CA, 
Limou S, Le Clerc S, Delaneau O, Zagury JF, 
Schuitemaker H, Van Manen D, Bream JH, 
Gomperts ED, Buchbinder S, Goedert JJ, 
Kirk GD, O’Brien SJ: Genome-wide associa-
tion study implicates PARD3B-based AIDS 
restriction. J Infect Dis 2011; 203: 1491–1502. 
 
